The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review

The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review

Juan Yang,1 Kyung-Min Shin,2 Alex Do,1 Dennis M Bierle,1 Abd Moain Abu Dabrh,3 Ziying Yin,4 Brent A Bauer,1 Arya B Mohabbat1 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA; 2KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Kore...

Full description

Bibliographic Details
Main Authors:	Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-03-01
Series:	Journal of Pain Research
Subjects:	fibromyalgia naltrexone low-dose naltrexone chronic pain review
Online Access:	https://www.dovepress.com/the-safety-and-efficacy-of-low-dose-naltrexone-in-patients-with-fibrom-peer-reviewed-fulltext-article-JPR

Similar Items

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
by: Karlo Toljan, et al.
Published: (2018-09-01)

A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
by: Sarah Partridge, et al.
Published: (2023-05-01)

Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
by: C. Noelle Driver, et al.
Published: (2023-04-01)

Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial
by: Tânia Maria Hendges de Paula, et al.
Published: (2023-07-01)

Low Dose Naltrexone - Efficacy and safety of off-label use therapy.
by: Andrzej Stańczak
Published: (2020-01-01)

RATIONALE FOR THE SELECTION OF AUXILIARY COMPONENTS FOR THE NALTREXONE HYDROCHLORIDE NASAL SPRAY
by: Y. M. Domnina, et al.
Published: (2019-01-01)

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series
by: McKenzie-Brown AM, et al.
Published: (2023-06-01)

Low-dose naltrexone as a treatment for vulvodynia: A case series
by: Renee T. Sullender, et al.
Published: (2025-03-01)

Approaches to the Development of a Low-dose Naltrexone Preparation in the Form of a Nasal Spray (Review)
by: Yu. M. Domnina, et al.
Published: (2021-02-01)

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
by: Praneet Dara, et al.
Published: (2023-06-01)

Precipitated withdrawal with kratom use following naltrexone administration
by: Jarka Courtney PharmD, BCPS, BCPP, et al.
Published: (2023-06-01)

Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study
by: Marcus NJ, et al.
Published: (2024-03-01)

Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients
by: Wei Qu, et al.
Published: (2025-01-01)

Thyroid Function of Former Opioid Addicts on Naltrexone Treatment
by: Ioannis Ilias, et al.
Published: (2001-01-01)

A study of predictors of retention to naltrexone maintenance therapy in patients with opioid use disorder: a prospective study
by: Burhan Bashir Lone, et al.
Published: (2024-08-01)

Efficacy of Naltrexone/Bupropion in Treatment of Binge Eating: A Systematic Review and Meta-Analysis
by: Mostafa Hossam-Eldin Moawad, et al.
Published: (2024-07-01)

Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practiceKey takeaways
by: Michael Kyle, et al.
Published: (2025-03-01)

Safety of naltrexone in patients with cirrhosis
by: Rachel Thompson, et al.
Published: (2024-07-01)

Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment
by: Kristine A.U. Pallesen, et al.
Published: (2019-09-01)

Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
by: Anar Isman, et al.
Published: (2024-03-01)

Enhancement of Cisplatin Nephrotoxicity by Morphine and Its Attenuation by the Opioid Antagonist Naltrexone
by: Atefeh Aminian, et al.
Published: (2016-07-01)

The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review
by: Raewyn Rees, et al.
Published: (2017-12-01)

Evaluation of Different Doses of Fentanyl in Controlling Agitation in Acute Opioid Withdrawal Syndrome Induced by Naltrexone Misuse
by: Farzad Gheshlaghi, et al.
Published: (2012-03-01)

Microbiological Estimation of Nasal Spray Containing Naltrexone Hydrochloride
by: Yu. M. Domnina, et al.
Published: (2020-11-01)

Naltrexone-induced acute generalized exanthematous pustulosis
by: Jason Eakes, BS, et al.
Published: (2023-09-01)

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study
by: Laura Micheli, et al.
Published: (2020-09-01)

Naltrexone Implant for Opioid Use Disorder
by: Amber N. Edinoff, et al.
Published: (2021-12-01)

Exploring genetic predictors of naltrexone treatment response in opioid use disorder
by: Е. A. Blokhina ., et al.
Published: (2019-12-01)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
by: Xuechan Lyu, et al.
Published: (2018-03-01)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
by: Mitchell R. K. L. Lie, et al.
Published: (2018-03-01)

Study of Acute Toxicity and Irritant Effect of Nasal Spray Naltrexone Hydrochloride
by: Yu. M. Domnina, et al.
Published: (2021-05-01)

Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone
by: Aimee N. Jensen, PharmD, BCPS, BCPP, et al.
Published: (2021-05-01)

Acute Myocardial Infarction following Naltrexone Consumption; a Case Report
by: Bita Dadpour, et al.
Published: (2016-12-01)

Naltrexone-Induced Cardiac Function Improvement is Associated With an Attenuated Inflammatory Response and Lipid Perioxidation in Volume Overloaded Rats
by: Lukas Dehe, et al.
Published: (2022-06-01)

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines
by: Robert L. Joyner, et al.
Published: (2024-08-01)

The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials
by: Yang Liu, et al.
Published: (2024-04-01)

Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect
by: V. Ya Palatkin, et al.
Published: (2019-12-01)

Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications
by: Elena R. Beauregard, PharmD, BCPS, et al.
Published: (2024-04-01)

Design and Characterization of Spray-Dried Chitosan-Naltrexone Microspheres for Microneedle-Assisted Transdermal Delivery
by: Abayomi T. Ogunjimi, et al.
Published: (2020-05-01)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
by: Melissa Velasquez, et al.
Published: (2019-10-01)